Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC
Clinical trial NCT05394415 · UNKNOWN
Trial details
- NCT number
- NCT05394415
- Sponsor
- Jiangsu Cancer Institute & Hospital
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-01
- Primary completion
- 2024-04-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.